Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Tscan Therapeutics Inc (NASDAQ: TCRX) was $1.12 for the day, down -9.68% from the previous closing price of $1.24. In other words, the price has decreased by -$9.68 from its previous closing price. On the day, 1.47 million shares were traded. TCRX stock price reached its highest trading level at $1.25 during the session, while it also had its lowest trading level at $1.08.
Ratios:
Our analysis of TCRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.06 and its Current Ratio is at 7.06. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.51.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, BTIG Research on May 16, 2024, initiated with a Buy rating and assigned the stock a target price of $12.
On May 13, 2024, Needham started tracking the stock assigning a Buy rating and target price of $11.
On June 22, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.Wedbush initiated its Outperform rating on June 22, 2023, with a $8 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 19 ’25 when Lynx1 Capital Management LP bought 1,388,794 shares for $1.20 per share. The transaction valued at 1,666,553 led to the insider holds 6,746,141 shares of the business.
Lynx1 Capital Management LP bought 1,200,000 shares of TCRX for $1,440,000 on May 20 ’25. The 10% Owner now owns 7,946,141 shares after completing the transaction at $1.20 per share. On Dec 13 ’24, another insider, Lynx1 Capital Management LP, who serves as the 10% Owner of the company, bought 100,000 shares for $2.90 each. As a result, the insider paid 290,140 and bolstered with 5,357,347 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TCRX now has a Market Capitalization of 63557752 and an Enterprise Value of -57787248. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.13 while its Price-to-Book (P/B) ratio in mrq is 0.36. Its current Enterprise Value per Revenue stands at -8.302 whereas that against EBITDA is 0.409.
Stock Price History:
The Beta on a monthly basis for TCRX is 1.02, which has changed by -0.7820738 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, TCRX has reached a high of $6.22, while it has fallen to a 52-week low of $1.02. The 50-Day Moving Average of the stock is -42.59%, while the 200-Day Moving Average is calculated to be -36.82%.
Shares Statistics:
TCRX traded an average of 498.54K shares per day over the past three months and 995240 shares per day over the past ten days. A total of 52.47M shares are outstanding, with a floating share count of 46.42M. Insiders hold about 18.20% of the company’s shares, while institutions hold 59.62% stake in the company. Shares short for TCRX as of 1760486400 were 1675616 with a Short Ratio of 3.36, compared to 1757894400 on 1722543. Therefore, it implies a Short% of Shares Outstanding of 1675616 and a Short% of Float of 3.5900000000000003.
Earnings Estimates
. The current market rating for Tscan Therapeutics Inc (TCRX) reflects the collective analysis of 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.18 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$0.89 and -$2.13 for the fiscal current year, implying an average EPS of -$1.25. EPS for the following year is -$1.18, with 6.0 analysts recommending between -$0.77 and -$1.73.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $2.5M to a low estimate of $500k. As of. The current estimate, Tscan Therapeutics Inc’s year-ago sales were $1.05MFor the next quarter, 5 analysts are estimating revenue of $1.68M. There is a high estimate of $2.5M for the next quarter, whereas the lowest estimate is $400k.
A total of 6 analysts have provided revenue estimates for TCRX’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $6.2M, resulting in an average revenue estimate of $9.91M. In the same quarter a year ago, actual revenue was $2.82M
